Utility of antiPax5 in the diagnosis of lymphoproliferative disorders and neoplasia in mice.
B-Cell-Specific-Activator-Protein, Immunohistochemistry, Lymphoproliferative-Disorders, Mice-Inbred-C3H, Neoplasms-Experimental
see Reprint Collection (a pdf is available)
Comp Med 2008 Jun; 58(3):246-52.
CD45R/B220 antigen (B220) is a common mouse panB-cell marker used for paraffin-embedded tissues. However, antiB220 has limited specificity in diagnostic pathology because the B220 antigen is expressed on subsets of cytotoxic T lymphocytes and natural killer cells, on plasmacytic dendritic cells, and on T lymphocytes of mice with the lymphoproliferative disorder associated with Fas (lymphoproliferative mutant mouse, B6.MRL-Fas(lpr/J)) or Fas ligand (generalized lymphoproliferative disease mutant mouse, C3H/ HeJ-Fasl(gld/J) or B6Smn.C3-Fasl(gld/J)). In addition, mouse B lymphocytes vary in the amount of B220 expressed, and some subsets of mouse B lymphocytes do not express B220 at all. In comparison, Pax5 expression (detected by immunohistochemistry using antiPax5) offers greater specificity and sensitivity because of its earlier expression during B-cell differentiation, its ability to detect all committed B cells, and its restriction to the B-cell lineage. Here we describe the use of an antibody to human Pax5 in diagnostic pathology with formalin-fixed, paraffin-embedded mouse tissue.
Rehg, J E. and Sundberg, J P., "Utility of antiPax5 in the diagnosis of lymphoproliferative disorders and neoplasia in mice." (2008). Faculty Research 2000 - 2009. 1785.
Please contact the Joan Staats Library for information regarding this document.